DGIdb - LEUCOVORIN Drug Record

LEUCOVORIN chembl:CHEMBL1679 ApprovedAntineoplastic

Alternate Names:

LEUCOVORIN

Drug Info:

Drug Class	vitamins/minerals
Year of Approval	approved before 1982
Drug Class	antineoplastic adjuncts
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	adjuvant to chemotherapy

(4 More Sources)

Publications:

Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
Chen et al., 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system., Cancer Res.
Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
Hou Z et al., 2005, Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods., J Biol Chem
Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.
Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.
Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho
Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
Etienne-Grimaldi MC et al., 2010, Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients., Br J Clin Pharmacol
Huang MY et al., 2008, ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study., BMC Cancer
Paradiso et al., 2001, Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer., Br. J. Cancer
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
Etienne-Grimaldi MC et al., 2012, Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan., Br J Clin Pharmacol
Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.

LEUCOVORIN RUNX3

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17372756

Sources:
NCI
LEUCOVORIN DPYD

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12576451 11977552 31871216

Sources:
NCI CIViC PharmGKB
LEUCOVORIN XRCC3

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
LEUCOVORIN ABCG1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
LEUCOVORIN KLC1

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
LEUCOVORIN UMPS

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20647221 16818689

Sources:
PharmGKB
LEUCOVORIN RGS5

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25069475

Sources:
PharmGKB
LEUCOVORIN MTHFR

Interaction Score: 1.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593

Sources:
PharmGKB
LEUCOVORIN ERCC2

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20385995 20078613 18267032

Sources:
PharmGKB
LEUCOVORIN SHMT1

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22044939

Sources:
PharmGKB
LEUCOVORIN SLC19A1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16115875 21879757

Sources:
DTC PharmGKB
LEUCOVORIN ABCC5

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
LEUCOVORIN SELE

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24980946

Sources:
PharmGKB
LEUCOVORIN ERCC1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736 21057378

Sources:
PharmGKB
LEUCOVORIN GATA3

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
LEUCOVORIN APC

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type no benefit

PMIDs:
27626067

Sources:
JAX-CKB
LEUCOVORIN VEGFA

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 20125120

Sources:
PharmGKB
LEUCOVORIN ABCC4

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12036927

Sources:
NCI
LEUCOVORIN ABCG2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB
LEUCOVORIN TYMS

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Fusilev

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
LEUCOVORIN BAX

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11237386

Sources:
NCI
LEUCOVORIN ABCC2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736

Sources:
PharmGKB
LEUCOVORIN ERBB2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
27626067 28784859 26432108

Sources:
JAX-CKB
LEUCOVORIN GSTP1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LEUCOVORIN BRAF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fluorouracil + Leucovorin + Trastuzumab

Indication/Tumor Type rectum adenocarcinoma

Response Type no benefit

PMIDs:
27626067

Sources:
JAX-CKB
LEUCOVORIN MET

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
LEUCOVORIN KRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20921465

Sources:
CIViC
LEUCOVORIN EGFR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22486600

Sources:
PharmGKB

TEND: LEUCOVORIN
- Version: 01-August-2011
Alternate Names:

LEUCOVORIN Primary Drug Name

Drug Info:

Drug Class antineoplastic adjuncts

Year of Approval approved before 1982

Drug Class vitamins/minerals

Publications:
TdgClinicalTrial: LEUCOVORIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications adjuvant to chemotherapy

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: LEUCOVORIN

Version: 02-September-2020

Alternate Names:

CHEMBL1679 ChEMBL Drug ID

Drug Info:

Publications:

Wang L et al., 2011, Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase., J Med Chem

NCI: LEUCOVORIN

Version: 14-September-2017

Alternate Names:

C607 NCI drug code

Drug Info:

Publications:

Ogino et al., 2007, CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma., Virchows Arch.

Ishida et al., 2002, [A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT]., Gan To Kagaku Ryoho

Ichikawa et al., 2003, Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer., Clin. Cancer Res.

PharmGKB: leucovorin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther

Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J

Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One

JAX-CKB: Leucovorin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud

Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw

CIViC: LEUCOVORIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud

Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.

ChemblDrugs: chembl:CHEMBL1679
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Approval Status	Clinical Study
Response Type	no benefit

combination therapy	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

combination therapy	Fluorouracil + Leucovorin + Trastuzumab
Indication/Tumor Type	rectum adenocarcinoma
Response Type	no benefit

LEUCOVORIN Drug Record

LEUCOVORIN chembl:CHEMBL1679 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17372756

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12576451 11977552 31871216

Sources: NCI CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26352872

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20647221 16818689

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25069475

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20385995 20078613 18267032

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22044939

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16115875 21879757

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26352872

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24980946

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23314736 21057378

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24141364

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Clinical Study Response Type no benefit

PMIDs: 27626067

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25955730 20125120

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12036927

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24338217 24018773 20530282

Interaction Types & Directionality:

n/a

PMIDs:
17372756

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12576451 11977552 31871216

Sources:
NCI CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26352872

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20647221 16818689

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25069475

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29845393 29134491 27864592 27557140 25331073 24980946 23407049 20819423 20385995 18245544 17700593

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20385995 20078613 18267032

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22044939

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16115875 21879757

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26352872

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24980946

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23314736 21057378

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24141364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type no benefit

PMIDs:
27626067

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
25955730 20125120

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12036927

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name Fusilev

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
11237386

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23314736

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
27626067 28784859 26432108

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fluorouracil + Leucovorin + Trastuzumab

Indication/Tumor Type rectum adenocarcinoma

Response Type no benefit

PMIDs:
27626067

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a